Details of the Drug Reposition

General Information of This Drug (ID: DMSDSFX)

Drug Name
JNJ-75348780   DMSDSFX
Drug Type
Bispecific antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.